BioPharmSignal logoBioPharmSignal

Biotech News

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics (ABEO)Abeona TherapeuticsCompany update

ABEO (ABEO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is abeo.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAPRCapricor Therapeutics2026-06-08 13:25 EST

Capricor Therapeutics to Present at Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

OCGNOcugen2026-07-31 11:02 EST

Ocugen to Participate in Upcoming August Investor Conferences

OCGNOcugen2026-06-02 11:03 EST

Ocugen to Participate in Upcoming June Investor and Industry Conferences

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

TARAProtara Therapeutics2026-05-18 12:00 EST

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

View all latest news

Abeona Therapeutics

Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases. ZEVASKYN ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform. ABO-701 ABO-701 is an...

Recent company news

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ABEOAbeona Therapeutics2026-08-04 11:30 EST

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

ABEOAbeona Therapeutics2026-08-03 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-07-21 11:30 EST

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

ABEOAbeona Therapeutics2026-07-01 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
6.90 USD
Market cap
324.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States